EP Wealth Advisors LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,050 shares of the medical research company’s stock, valued at approximately $354,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. FMR LLC raised its holdings in shares of IQVIA by 24.7% during the first quarter. FMR LLC now owns 5,620,968 shares of the medical research company’s stock valued at $1,117,954,000 after acquiring an additional 1,111,803 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of IQVIA by 2.2% during the first quarter. Geode Capital Management LLC now owns 3,804,161 shares of the medical research company’s stock valued at $754,864,000 after acquiring an additional 81,501 shares in the last quarter. Lazard Asset Management LLC grew its stake in IQVIA by 1.0% in the fourth quarter. Lazard Asset Management LLC now owns 2,844,533 shares of the medical research company’s stock worth $582,814,000 after purchasing an additional 29,537 shares during the period. Longview Partners Guernsey LTD grew its stake in IQVIA by 9.4% in the first quarter. Longview Partners Guernsey LTD now owns 2,707,910 shares of the medical research company’s stock worth $538,576,000 after purchasing an additional 232,872 shares during the period. Finally, Amundi grew its stake in IQVIA by 0.6% in the fourth quarter. Amundi now owns 2,230,818 shares of the medical research company’s stock worth $494,193,000 after purchasing an additional 13,947 shares during the period. Institutional investors own 86.82% of the company’s stock.
IQVIA Stock Down 0.6 %
IQV stock opened at $211.71 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $241.86. The business’s 50-day moving average is $220.12 and its two-hundred day moving average is $208.08. The company has a debt-to-equity ratio of 2.16, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $38.77 billion, a price-to-earnings ratio of 36.44, a P/E/G ratio of 2.15 and a beta of 1.37.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the company. Stifel Nicolaus upped their price target on IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Truist Financial upped their price target on IQVIA from $244.00 to $260.00 and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Barclays upped their price target on IQVIA from $230.00 to $250.00 in a research note on Tuesday, June 27th. StockNews.com initiated coverage on IQVIA in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Finally, Citigroup increased their target price on IQVIA from $200.00 to $225.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $252.00.
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Five stocks we like better than IQVIA
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- How to Invest in the Healthcare Sector
- MarketBeat Week in Review – 9/11 – 9/15
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.